Navigation Links
Chimerix to Present at Two Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Nov. 12 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, announced today that Kenneth I. Moch, Chief Operating Officer, will present a corporate overview at two upcoming investor conferences. Mr. Moch will discuss the company's technology assets and pipeline, including CMX001, a broad-spectrum antiviral being developed for the treatment of BK virus and cytomegalovirus in immunocompromised transplant patients and as a biodefense countermeasure in the event of a smallpox release.

Mr. Moch will speak at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009 at 9:30 a.m. ET and at the Piper Jaffray 21st Annual Health Care Conference on Tuesday, December 1, 2009 at 9:50 a.m. ET. Both meetings are being held in New York City.

About Chimerix

Chimerix, Inc., is developing antiviral therapeutics to treat life-threatening diseases. Led by a world-class antiviral drug development team, Chimerix is advancing programs to address cytomegalovirus (CMV), BK virus, smallpox, human immunodeficiency virus (HIV), hepatitis C virus (HCV), respiratory syncytial virus (RSV) and influenza. The company's lead compound, CMX001, is currently in Phase 1 and 2 clinical studies for the treatment of BK virus and CMV, potentially deadly infections among immunocompromised patients. CMX001 is also being evaluated for use as a biodefense countermeasure in the event of a smallpox release. Chimerix has received financing from leading venture capital firms, including Canaan Partners, Alta Partners, Sanderling Ventures, Frazier Healthcare Ventures and Asset Management Company, in addition to U.S. Government grants. Additional information about Chimerix and its antiviral drug development programs may be found online at

SOURCE Chimerix, Inc.

SOURCE Chimerix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
2. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
3. Tobira Therapeutics Announces Presentation of TBR-652 Data at European AIDS Conference
4. Trubion Announces Acceptance of Two Presentations on Its TRU-016 Product Candidate at the 2009 ASH Annual Meeting
5. Onyx Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
6. Webcast Alert: Isis Pharmaceuticals and Genzyme Corporation to Present Mipomersen Phase 3 Data in HoFH During AHA
7. Hologic to Present at NASDAQ OMX 23rd Investor Program in London
8. Accera, Inc. To Present at Lazard Capital Markets 6th Annual Healthcare Conference
9. Abaxis, Inc. to Present at the Sidoti & Company Second Annual New York Institutional Investor Forum
10. CryoLife to Present at Upcoming Investor Conferences in New York
11. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)... 2015 Allergan plc (NYSE: AGN ... Therapeutics, a start-up  biotechnology company focused on the ... and funded by the F-Prime Biomedical Research Initiative ... an exclusive collaboration to support the discovery and ... (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... Israel , November 25, 2015 ... "New Investors"), pursuant to which BioLight and the New ... IOPtima Ltd. subsidiary ("IOPtima") via a private placement. The ... of its innovative IOPtimate™ system used in the treatment ... approval pathway process for the IOPtimate™ system with the ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... scholarships for people struggling with eating disorders as a result of the $20,000 ... annual event, held at Fox Run Golf Club in Eureka, will help individuals ...
(Date:11/25/2015)... ... 25, 2015 , ... "When I underwent breast reconstruction following ... uncomfortable," said an inventor from Bronx, N.Y. "In order to meet my own ... BRA for added comfort and support. The bra is easier to put on ...
(Date:11/25/2015)... ... , ... An unlikely combination of recycled plastic shopping bags ... people to have a more dignified and comfortable night’s sleep. , Residents of ... plastic bags into sleeping mats for the homeless. The project, according to ...
(Date:11/25/2015)... ... 25, 2015 , ... Bcureful—a non-profit organization devoted to advancing ... public awareness of the disorder while helping to bring expert medical care and ... bolster progress at the Tuberous Sclerosis Complex Center at Ann & Robert H. ...
(Date:11/25/2015)... ... , ... Students and parents have something to be thankful for this Thanksgiving ... awards. California Casualty is proud to support the contest designed to utilize ... driving, the number one killer of young drivers. , Almost 1,000 entries of ...
Breaking Medicine News(10 mins):